| Non-CVD (n = 4150) | CVD (n = 371) |  | ||
---|---|---|---|---|---|
 | median or% | IQR* | median or% | IQR* | P value |
Age (years) | 54 | 21 | 64 | 16 | <.0001‡ |
Male Gender | 45.7% (1898) | Â | 52.8% (196) | Â | .0086 |
Smoking status |  |  |  |  | <.0001†|
   Ex smoker | 13.3% (553) |  | 20.2% (75) |  |  |
   Current smoker | 14.9% (620) |  | 21.2% (78) |  |  |
Waist circumference (men, cm) | 87.5 | 12.5 | 88.0 | 11.0 | .2384 |
Waist circumference (women, cm) | 82.5 | 13.0 | 84.5 | 13.0 | .0165 |
Body mass index (kg/m2) | 24.6 | 5.0 | 24.9 | 4.3 | .4409 |
Duration of diabetes (Years) | 5 | 9 | 9 | 10 | <.0001‡ |
Systolic blood pressure (mmHg) | 132 | 25 | 141 | 25 | <.0001‡ |
Diastolic blood pressure (mmHg) | 75 | 14 | 75 | 13 | .1313‡ |
HbA1c (%) | 7.2 | 2.1 | 7.7 | 2.6 | <.0001‡ |
Spot urine albumin creatinine ratio (mg/mmol) | 1.55 | 5.75 | 7.13 | 54.8 | <.0001‡ |
eGFR (ml min-1 1.73 m-2) ξ | 109 | 39 | 93 | 41 | <.0001‡ |
LDL-C (mmol/L) | 3.1 | 1.2 | 3.4 | 1.3 | <.0001‡ |
   ≥3.0 mmol/L | 56.1%(2330) |  | 69.0%(256) |  | <.0001†|
HDL-C (mmol/L) | 1.28 | 0.45 | 1.18 | 0.45 | <.0001‡ |
   HDL-C <1.0 in male or 1.3 in female | 23.8%(987) |  | 25.9%(96) |  | .3655†|
Triglyceride (mmol/L) | 1.27 | 0.97 | 1.40 | 1.01 | .0031‡ |
Drug use at enrolment | Â | Â | Â | Â | Â |
Use of antihypertensive drugs at enrolment | 29.7%(1231) |  | 42.3%(157) |  | <.0001†|
Drug use during follow-up | Â | Â | Â | Â | Â |
Use of statins during follow-up | 22.7%(942) |  | 22.6%(84) |  | .9799†|
Use of fibrates during follow-up | 6.41%(266) |  | 4.58%(17) |  | .1639†|
Use of other lipid lowering drugs during follow-up | 0.29% (12) |  | 0.27% (1) |  | .3832 ††|
Use of RAS inhibitors during follow-up | 48.9% (2029) |  | 62.5% (232) |  | <.0001†|
Use of gliclazide during follow-up | 43.7% (1814) |  | 37.2% (138) |  | .0152†|
Use of rosiglitazone during follow-up | 4.9% (204) |  | 1.6% (6) |  | .0038†|
Use of other oral antidiabetic drugs during follow-up | 79.0% (3280) |  | 80.3% (298) |  | .5587†|
Use of insulin during follow-up | 32.4%(1345) |  | 45.0%(167) |  | <.0001†|
Events during follow-up | Â | Â | Â | Â | Â |
Death during follow-up | 5.42% (225) |  | 27.5%(102) |  | <.0001†|